Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation é uma condição cutânea caracterizada pelo aumento da pigmentação da pele após inflamação da pele. Postinflammatory hyperpigmentation pode ser causada por exposição prolongada ao sol, inflamação ou outras lesões na pele, incluindo aquelas relacionadas à acne. Pessoas com tons de pele mais escuros geralmente são mais propensas à hiperpigmentação com exposição excessiva ao sol.
☆ Nos resultados do Stiftung Warentest de 2022 da Alemanha, a satisfação do consumidor com o ModelDerm foi apenas ligeiramente inferior do que com as consultas pagas de telemedicina.
References
Postinflammatory hyperpigmentation (PIH) é um problema de pele frequente que ocorre após uma inflamação ou lesão na pele. Tende a durar muito tempo e é pior em pessoas com tons de pele mais escuros (Fitzpatrick skin types III–VI) . Embora muitas vezes melhore por si só, isso pode demorar um pouco, por isso o tratamento geralmente é necessário por um longo tempo. Combinar diferentes tratamentos funciona melhor.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation é uma sequela comum de inflamação da pele. Tende a afetar indivíduos de pele mais escura com mais severidade e frequência. Estudos mostram que questões como postinflammatory hyperpigmentation estão entre os principais motivos pelos quais pessoas com tons de pele mais escuros procuram atendimento dermatológico. O tratamento precoce é crucial para a resolução do postinflammatory hyperpigmentation e geralmente começa com o manejo da condição inflamatória inicial. A primeira linha de tratamento normalmente envolve o uso de agentes tópicos que iluminam a pele junto com protetor solar para proteção. Esses agentes, como hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , podem efetivamente reduzir a pigmentação excessiva. Além disso, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy também são utilizados como agentes despigmentantes, surgindo novos tratamentos. Embora os tratamentos tópicos sejam geralmente eficazes para hiperpigmentação superficial, procedimentos (laser, chemical peel) podem ser necessários para casos persistentes. É importante ter cautela com esses tratamentos para evitar irritação e agravamento do postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
